Home
Home

wet-AMD

Lpath Restarts NEXUS Trial; Breathes New Life Into Shares

Lpath Restarts NEXUS Trial; Breathes New Life Into Shares
Seeking Alpha

Lpath Begins iSONEP Dosing in Nexus Phase 2 Study

Lpath Begins iSONEP Dosing in Nexus Phase 2 Study
Yahoo

Regeneron drops 6% after Ophthotech reports positive data

Regeneron drops 6% after Ophthotech reports positive data
The Fly on the Wall

Regeneron Drops as Eye Drug Shown Similar to Roche's Lucentis

Regeneron Drops as Eye Drug Shown Similar to Roche's Lucentis
Bloomberg Businessweek

Regeneron Soars on Eye-Drug Rival Setback

Regeneron Soars on Eye-Drug Rival Setback
TheStreet.com

News

QLT Announces Toronto Stock Exchange Approval of Increased Share Repurchase Program
Yahoo/Globe NewsWire
»

News

Lpath's iSONEP Is Well Tolerated at All Dose Levels in a Phase 1 Trial in Wet-AMD Patients
Yahoo/MarketWire
»